This article discusses clinical data for noncovalent Bruton tyrosine kinase inhibitors (BTKis), novel strategies in CLL, and the practical management of BTKi toxicities.
Rebecca Pokorny, PharmD, BCPS, BCOP
Advertisement
Articles by Rebecca Pokorny, PharmD, BCPS, BCOP
This article provides an overview of data supporting the utility of covalent Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia and details important considerations when choosing among agents.
Integrating immunotherapies will continue to improve patient outcomes and quality of life.
Advertisement
Latest Updated Articles
Recent Clinical Trials Reveal Important Updates in Adjuvant Therapy for Resectable Non–Small Cell Lung CancerPublished: October 20th 2023 | Updated:
Chronic Lymphocytic Leukemia: A Review of Noncovalent BTK Inhibitors, Novel Agents, and Toxicity Management of BTK InhibitorsPublished: August 19th 2024 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Expands Approval of Sotatercept-csrk for Pulmonary Arterial Hypertension
2
States Push Forward on Insurance Mandates for GLP-1 and Obesity Treatments
3
Clinical Data Support Use of Low-Carbon Version of Albuterol Metered Dose Inhaler for Asthma
4
Expert Insights on Key Data from IMS 2025
5
